Oral administration of epigallocatechin-3-gallate (EGCG) (400 mg capsules, three times daily) to BC patients undergoing radiotherapy showed that EGCG suppressed NF-κB expression and AKT phosphorylation in the patients’ serum. This evidence concerns the gene AKT1 and breast cancer.